Archive

Overcoming Barriers in the Treatment of Limited-Stage Small Cell Lung Cancer With a Focus on Low- and Middle-Income Countries: A Narrative Review

If you treat SCLC in India, this maps the real constraints — late staging, radiotherapy access, chemo logistics — that decide whether concurrent chemoradiation is actually deliverable.

Oncology · Cureus · 4h

Impact of Demographic and Socioeconomic Factors on Survival Associated With Androgen Receptor Pathway Inhibitor Use in Metastatic Prostate Cancer: An Analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Database

SEER-Medicare data show ARPI survival gains in metastatic prostate cancer are uneven across demographic and socioeconomic groups — check whether your eligible patients are actually being offered it.

Oncology · Cureus · 15h

Obesity and Cancer Risk in Young Adults in Korea : A Nationwide Health Screening Cohort Study.

Reinforces weight as a modifiable cancer risk factor in patients under 40, supporting earlier counselling on BMI even in young, otherwise healthy adults.

Oncology · Annals · 15h

AI model uses face photos to estimate biological age, predict survival risk in cancer patients

A face photo-derived biological age score predicted survival in cancer patients; it is not validated for treatment decisions, so treat it as a research triage signal only.

Oncology · ETHealthworld · 1d

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

A first-in-class EGFR/HER3 bispecific ADC offers a new mechanism for heavily pretreated HR+/HER2- disease, where endocrine and chemotherapy options are largely exhausted.

Oncology · Lancet · 2d

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

If sac-TMT beats physician's choice after platinum and immunotherapy, it gives your post-progression endometrial cancer patients a TROP2-directed option where few exist.

Oncology · Lancet · 2d

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

Adds a perioperative durvalumab pathway for borderline-resectable NSCLC, with MDT triage deciding who proceeds to surgery versus CRT plus consolidation.

Oncology · Nature Medicine · 2d

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

If this HER3 ADC beats chemotherapy after TKI failure, it gives your EGFR-mutated patients a new option before or alongside platinum doublets.

Oncology · Lancet · 2d

Advances in the management of renal cell carcinoma.

Molecular subtyping now refines RCC diagnosis beyond histology, so imaging and selective biopsy decisions increasingly depend on tumour biology rather than stage alone.

Oncology · BMJ · 2d

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

A bispecific EGFR-HER3 ADC beat platinum chemotherapy after third-generation TKI failure in EGFR-mutated NSCLC, offering a targeted option where chemotherapy is the current default.

Oncology · Lancet · 2d

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

If pembrolizumab beats carboplatin-paclitaxel on PFS in dMMR disease, your first-line choice for these patients shifts from chemo to checkpoint monotherapy.

Oncology · Lancet · 2d

Spontaneous Tumor Lysis Syndrome in a Critically Ill Patient With Cytology Favoring Small Cell Carcinoma: A Case Report

Uric acid rose to a documented peak of 12 mg/dL and LDH reached 3,608 U/L, with progressive hyperkalemia, hyperphosphatemia, hypocalcemia, acidosis and anuria; she died of refractory shock and multiorgan failure

Oncology · Cureus · 2d

Contemporary Management of Colorectal Liver Metastases

Resectability is no longer the sole gate: molecular profile and functional liver reserve now decide whether your CRLM patient goes straight to surgery or to conversion therapy first.

Oncology · Cureus · 2d

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.

A next-generation KRAS G12C inhibitor beat sotorasib/adagrasib head-to-head in previously treated NSCLC — expect divarasib to enter your second-line sequencing decisions.

Oncology · NEJM · 3d

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.

If the combination beats pembrolizumab-chemotherapy in PD-L1-negative NSCLC, it offers a chemotherapy-sparing first-line option for a group with few good choices.

Oncology · NEJM · 3d

Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.

For EGFR-mutant NSCLC progressing on osimertinib, adding a MET inhibitor targets the commonest resistance mechanism — but requires confirming MET amplification or overexpression first.

Oncology · NEJM · 3d

Comparison of Acute Hematological Toxicities Between Three-Dimensional Conformal Radiotherapy (3DCRT) and Intensity-Modulated Radiotherapy (IMRT) in Locally Advanced Cervical Cancer

During EBRT, overall haematological toxicity was 97.14% with 3DCRT versus 77.14% with IMRT (p = 0.012); leukopenia 65% versus 34% (p = 0.05). After ICRT, overall toxicity 97.14% versus 71.43% (p = 0.006) and anaemia 85.7% versus 51.4% (p = 0.002).

Oncology · Cureus · 3d

Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer.

A HER2 bispecific plus albumin-bound docetaxel may offer a first-line alternative to THP, but wait for the survival and toxicity data before switching regimens.

Oncology · NEJM · 4d

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.

If perioperative durvalumab plus neoadjuvant enfortumab vedotin improves outcomes in cisplatin-ineligible patients, it reshapes who you can offer bladder-sparing curative-intent therapy to.

Oncology · NEJM · 4d

Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.

Five-year data confirm the fixed-dose relatlimab-nivolumab combination's durable survival benefit over nivolumab alone, supporting it as a first-line option in untreated advanced melanoma.

Oncology · Nature Medicine · 4d

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.

Adds a GDF-15 antibody to neoadjuvant nivolumab in MIBC; check the pathological response and toxicity data before considering this combination for cisplatin-ineligible patients.

Oncology · Nature Medicine · 4d

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

If halving the FTD-TPI exposure days preserves survival, you can cut haematological and GI toxicity in heavily pretreated patients without sacrificing efficacy.

Oncology · Lancet · 4d

Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer.

Median overall survival 21.1 months with tarlatamab-durvalumab versus 12.7 months with durvalumab (HR 0.42; 95% CI 0.32 to 0.54; P<0.001). Median progression-free survival 7.4 versus 1.9 months (HR 0.34; 95% CI 0.28 to 0.42).

Oncology · NEJM · 4d

STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion

If AI-guided discovery using large tumour datasets yields candidates faster, oncology trial options for your patients could widen within a few years.

Oncology · STAT News — Health Tech · 4d

Clinical Outcomes and Safety of Spatially Fractionated Radiotherapy for Malignant Tumors: A Systematic Review and Evidence Map

SFRT delivers ablative central doses with sparing of surrounding tissue; this map shows where comparative evidence is still missing before you adopt it for bulky or radioresistant tumors.

Oncology · Cureus · 4d

Central Nervous System Progression During Longitudinal Treatment of Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer: A Real-World Cohort Study

CNS progression still occurs on CNS-active ALK-TKIs; track cumulative drug exposure across lines, not just first-line choice, when timing MRI surveillance.

Oncology · Cureus · 4d

Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer: The HORIZON-Breast06 Randomized Clinical Trial.

If the ADC beats physician's-choice chemo in ERBB2-low disease, it opens a targeted option for the large HER2-low group currently offered conventional chemotherapy.

Oncology · JAMA · 5d

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

A first-in-class T cell agonist that targets Vβ6/Vβ10 subsets rather than checkpoint pathways offers a new mechanism for patients whose tumours have already progressed on immunotherapy.

Oncology · Nature Medicine · 5d

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.

Primary DFS endpoint not met: median 23.8 versus 21.2 months (HR 0.85, P = 0.5329). Grade ≥3 adverse events 10.4% versus 14.6%; serious AEs 6.3% versus 8.3%.

Oncology · Nature Medicine · 5d

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma.

High versus low naive-like (CCR7+CD45RA+) T cells in the product gave prolonged PFS: hazard ratio 0.46 (95% CI 0.31-0.68), with no impact on safety.

Oncology · Nature Medicine · 5d

Routes to Diagnosis and Stage at Diagnosis of Colorectal Cancer in Patients Aged ≥ 50 Years: A Multicentre Retrospective Cohort Study From North Wales, UK

Which referral route a patient takes still predicts their CRC stage, so how you triage rectal bleeding and FIT results directly shapes whether they present operable.

Oncology · Cureus · 5d

Extragenital Lichen Sclerosus and Granulomatous Dermatitis in a Patient Treated With Nivolumab and Ipilimumab for Malignant Melanoma: A Case Report

IrAEs can present sequentially over months on dual checkpoint blockade; biopsy unusual rashes rather than assuming a single drug reaction, since management may differ.

Oncology · Cureus · 5d

Clear Skin, Vanishing Brows: Trichoscopy-Confirmed Eyebrow Alopecia Areata Associated With Secukinumab

PASI fell from 36.9 to 15.6 at week 8 and 0 at week 16. Bilateral eyebrow thinning appeared at week 16; trichoscopy showed black dots, circle hairs and short vellus hairs. Regrowth complete three months after stopping.

Oncology · Cureus · 5d

An Unusual Thoracic Presentation of Multiple Myeloma: Rib-Based Paraskeletal Plasmacytoma Mimicking a Lung Mass

Biopsy showed CD38-positive kappa-restricted plasma cells; marrow had 30% clonal plasma cells on trephine immunohistochemistry (15.9% by flow cytometry), with severe anemia and multifocal lytic disease. He died 67 days after admission.

Oncology · Cureus · 6d

Initial Outcomes of GammaTile Brachytherapy From a Single Institution: A Case Series

Implanted at resection, it delivers most radiation before adjuvant therapy would normally start — relevant if you refer brain tumour patients for post-op radiotherapy.

Oncology · Cureus · 6d

Paraneoplastic Hypertrophic Osteoarthropathy in the Setting of Dual Primary Malignancies: Follicular Thyroid Carcinoma and Metastatic Colon Adenocarcinoma

Clubbing and painful periostitis can be the presenting sign of an occult second malignancy; consider paraneoplastic HOA when joint pain accompanies cancer.

Oncology · Cureus · 6d

Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial.

3-year disease-free survival was 100% (97·5% CI 100-100) and 5-year overall survival 100% (95% CI 100-100) at median postoperative follow-up of 58·7 months.

Oncology · Lancet · 7d

Short-Course Preoperative Breast Radiotherapy: A Strategy to Reduce Financial Toxicity in Early-Stage Breast Cancer

No primary outcome reported. Five-fraction APBI is described as economically advantageous yet underutilised; whether preoperative radiotherapy reduces financial toxicity remains uncertain, and the institutional savings estimate is unpublished and not validated by time-driven activity-based costing

Oncology · Cureus · 7d

Myocardial Infarction in a Patient With Chronic Lymphocytic Leukemia: Acalabrutinib-Related Dehoming as a Potential Culprit

STEMI occurred 28 days after acalabrutinib initiation, with absolute lymphocyte count 261 x 109/L on admission. Course included cardiac arrest, third-degree AV block needing temporary pacing, PCI with IABP, and parietal and occipital strokes; she was discharged home.

Oncology · Cureus · 7d

Standalone Complete Decongestive Therapy Versus Combined Treatment With Kinesio Taping for Reducing Upper Limb Breast Cancer-Related Lymphedema After Axillary Dissection: A Randomized Clinical Trial

Adding kinesio taping to decongestive therapy was tested against CDT alone in 40 post-axillary-dissection women — know whether the extra taping buys measurable limb volume before you refer.

Oncology · Cureus · 7d